P00001606T0076|37 50|5-nucleotidase
P00008171T0000|30 47|hyperbilirubinemia
P00008997A0472|4 6|CSF
P00008997A0472|7 10|HCO3
P00008997A0472|34 40|CSF PCO2
P00013683A0210|53 56|VCO2
P00013683A0210|68 78|ventilation
P00015731A0090|63 75|acetazolamide
P00015731A0090|78 90|methazolamide
P00015731A0090|92 107|dichlorphenamide
P00015731A0090|214 215|pH
P00022143T0000|20 30|etoperidone
P00029555A0861|31 42|quantitation
P00029953T0045|0 14|Characteristics
P00030183T0000|18 28|association
P00030183T0000|33 38|HLA-B5
P00030937A0119|0 3|SGPT
P00030937A0119|5 8|SGOT
P00033873T0001|27 30|GGTP
P00038408T0000|9 19|stimulation
P00038408T0000|29 47|alpha-autoreceptors
P00038408T0000|70 85|alpha-methyldopa
P00038408T0000|89 91|FLA
P00050628A0202|2 4|IgG
P00055040A0000|3 14|out-patients
P00055040A0000|70 87|immunofluorescence
P00055040A0000|157 166|FR-antigen
P00055040A0000|237 239|HPF
P00055040A0000|243 254|cryoglobulin
P00056837A0000|5 21|mediastinoscopies
P00056837A0000|74 84|operability
P00056901A0308|27 46|hydroxy-ethyl-starch
P00060529A0695|27 42|acquisition-rate
P00060529A0695|215 218|A.B.
P00061478T0000|4 16|complications
P00061478T0000|19 33|catheterisation
P00063680T0000|19 31|galactosaemia
P00066874T0000|61 73|contamination
P00072928T0000|0 13|Serum-ferritin
P00072928T0000|27 42|haemochromatosis
P00073344A0367|41 51|lymphocytes
P00074758T0000|16 29|hypothyroidism
P00086313A0000|20 31|Legionnaires
P00089778A0000|3 15|concentration
P00089778A0000|58 68|plasminogen
P00089778A0000|70 82|C3-complement
P00089778A0000|113 115|FDP
P00096241A0087|0 1|T4
P00096241A0087|5 8|FT4I
P00096241A0087|136 138|EGA
P00100540T0000|28 41|susceptibility
P00101300A0257|36 37|T1
P00101300A0257|40 41|T2
P00101300A0257|43 44|T3
P00101300A0257|46 47|N0
P00101300A0257|49 50|N1
P00105401A0635|11 13|CBZ
P00105401A0635|17 19|DPH
P00105401A0635|36 47|interference
P00105401A0635|75 77|TBG
P00105401A0635|204 206|FT4
P00105401A0635|210 212|FT3
P00105903A0288|30 40|possibility
P00105903A0288|66 68|PEG
P00112627A0542|0 12|Pentobarbital
P00112627A0542|49 59|combination
P00112627A0542|86 98|normeperidine
P00112627A0542|111 121|anileridine
P00112627A0542|132 143|alphaprodine
P00113657A0628|11 15|gcm-2
P00113657A0628|39 49|improvement
P00114144A0189|114 125|similarities
P00117748T0000|0 11|Erythromycin
P00117748T0000|38 63|Corynebacterium diphtheriae
P00118044A0000|14 26|displacements
P00118044A0000|83 84|M2
P00119339A0400|118 128|myocarditis
P00119339A0400|142 153|degeneration
P00129659T0000|0 10|Variability
P00129659T0000|31 40|trisomy-21
P00129659T0000|79 81|IQs
P00130573T0054|0 2|VII
P00131739T0001|35 45|populations
P00133214T0064|40 43|USSR
P00136175A1137|3 13|maintenance
P00136175A1137|140 150|enlargement
P00136175A1137|153 155|ECA
P00137671A0896|5 16|observations
P00137671A0896|50 59|VIII-ratio
P00139624A0318|18 31|administration
P00139827A0000|0 16|Radioimmunoassays
P00139827A0000|19 30|pregnenolone
P00139827A0000|32 43|progesterone
P00139827A0000|45 66|dehydroepiandrosterone
P00139827A0000|67 69|DHA
P00139827A0000|74 90|alpha-hydroxy-DHA
P00142718A0156|93 102|99mTc-EHDP
P00149899T0001|29 39|development
P00150066A0100|33 43|coagulation
P00154430A0906|35 46|localization
P00154430A0906|73 85|transcription
P00155973A0387|194 198|min-1
P00155973A0387|237 241|min-1
P00159600A0871|0 1|SV
P00159600A0871|17 19|SHR
P00167544A0067|25 39|microdissection
P00173860A0475|129 140|disturbances
P00173860A0475|143 153|elimination
P00176742T0000|0 10|Polyglactin
P00188387A0975|9 20|lipoproteins
P00188387A0975|75 76|FH
P00196255A0000|114 126|verbalization
P00196255A0000|176 186|bizarreness
P00198510T0000|0 10|Innervation
P00201881A0487|45 55|correlation
P00201881A0487|63 68|PI ACTH
P00205074A0000|7 22|hypophosphatemia
P00209664A0836|10 20|correlation
P00209664A0836|95 105|correlation
P00210220X0000|9 22|neurochemistry
P00211881A0602|126 128|PBB
P00219533T0001|0 11|Distribution
P00219533T0001|15 26|correlations
P00219533T0001|59 69|populations
P00219565A0172|40 50|transfusion
P00219674A0000|0 13|Technetium-99m
P00219674A0000|22 34|pyrophosphate
P00219674A0000|45 55|scintigrams
P00221725A0523|85 95|neutrophils
P00222102A0227|57 67|vitamin-D-3
P00222102A0227|157 169|normalisation
P00222102A0227|172 184|serum-calcium
P00222827A0000|11 21|sensitivity
P00222827A0000|33 44|diisocyanate
P00222827A0000|45 47|TDI
P00222827A0000|107 121|hyperreactivity
P00224013A0661|5 7|VO2
P00224013A0661|95 104|beta-Block
P00224013A0661|216 226|utilization
P00224013A0661|392 405|vasodilatation
P00225352T0000|49 50|3H
P00227393T0000|12 45|25-hydroxyvitamin D3-24-hydroxylase
P00227393T0000|48 60|aminophylline
P00227610A1593|31 37|DBP mRNA
P00227610A1593|66 69|SV40
P00231555T0001|74 77|ACTH
P00232456T0000|12 14|RNA
P00232456T0000|32 35|MC29
P00232456T0000|39 41|MH2
P00234206T0000|54 64|arboviruses
P00234264A0164|104 114|aminopyrine
P00234626T0036|0 2|XXI
P00239014A0000|38 50|determination
P00239014A0000|78 81|CPIB
P00239169T0000|30 41|neuroleptics
P00240518A0000|33 45|determination
P00300314A0132|96 110|hospitalization
P00300314A0132|173 177|mg/m2
P00300314A0132|203 214|methotrexate
P00304310A0000|3 11|end-stage
P00304310A0000|54 64|retinopathy
P00304310A0000|76 88|stabilization
P00304806A0760|107 120|concentrations
P00321261A0104|20 34|prostaglandin E2
P00321261A0104|35 38|PGE2
P00321261A0104|44 63|prostaglandin F2alpha
P00330364A0132|74 76|BCG
P00330364A0132|138 152|BCG-vaccination
P00330364A0132|183 197|BCG-vaccination
P00330364A0132|230 241|laboratories
P00336547A0000|130 132|ICR
P00336547A0000|233 241|C57/BL/6J
P00336547A0000|259 264|BALB/c
P00336547A0000|266 272|CBA/LAC
P00336547A0000|277 282|C3H/eB
P00354315T0000|7 17|dysfunction
P00361340A0529|29 42|osteodystrophy
P00361340A0529|114 142|1,25-dihydroxycholecalciferol
P00361340A0529|157 168|significance
P00361340A0529|187 205|hyperparathyroidism
P00369397A0280|5 7|FSH
P00369397A0280|56 70|GnRH stimulation
P00369397A0280|82 84|FSH
P00377466A0188|37 38|LH
P00377466A0188|68 70|FSH
P00377466A0188|83 86|HPRL
P00377466A0188|100 101|E2
P00377466A0188|105 116|progesterone
P00377466A0188|123 134|testosterone
P00378735A0000|114 124|amoxycillin
P00378735A0000|188 202|chloramphenicol
P00383169A0000|79 89|apomorphine
P00383169A0000|97 107|derivatives
P00383169A0000|119 138|rye-ergot derivatives
P00384744T0000|23 34|hypofunction
P00393598A0198|47 49|ALS
P00401521A0138|39 49|ticarcillin
P00401676A0414|71 82|radiotherapy
P00409927A0570|32 44|staphylococci
P00409927A0570|66 77|streptococci
P00415543A0320|0 10|Recognition
P00415543A0320|33 43|radiographs
P00417301T0001|30 40|brucellosis
P00420460A0291|111 112|SQ
P00425547A0000|21 33|osteomyelitis
P00429151T0000|24 35|practitioner
P00429893A0000|49 60|implantation
P00429893A0000|164 174|stimulation
P00429949A0000|90 100|preparation
P00429949A0000|194 196|IRP
P00429949A0000|218 228|immunoassay
P00432615A0541|10 20|differences
P00432615A0541|91 103|gammaglobulin
P00432615A0541|134 145|interference
P00432615A0541|167 170|RIST
P00439618T0001|22 35|diethylamino-2
P00439618T0001|38 50|hydroxypropyl
P00445720A0263|27 29|SPG
P00445720A0263|55 56|LV
P00445720A0263|72 73|LA
P00450367T0000|26 37|hysterectomy
P00450367T0000|39 50|hysterectomy
P00450367T0000|89 100|hysterectomy
P00450559A0269|94 104|thermometer
P00450760T0001|0 15|Cryoglobulinemia
P00451192A0248|100 119|LV region-of-interest
P00463973A0000|119 121|SGA
P00464387A1185|6 17|measurements
P00464387A1185|75 78|ABPA
P00465223A0373|89 90|SD
P00465223A0373|93 96|mmHg
P00473229T0000|27 41|trichloroethane
P00473229T0000|43 59|trichloroethylene
P00473229T0000|61 79|tetrachloroethylene
P00473229T0000|95 105|development
P00473249T0000|58 77|electroencephalogram
P00474064A0205|77 87|mg.kg-1 I.V.
P00474064A0205|89 99|piritramide
P00474064A0205|115 127|phenoperidine
P00476020T0000|3 14|biochemistry
P00476572A0139|113 124|radiodensity
P00479222A0682|142 145|PECF
P00484177A0242|97 99|VT.
P00485615A0935|158 169|pancreatitis
P00485615A0935|176 186|performance
P00494659A0391|15 25|metabolites
P00494659A0391|32 46|3-carboxyphenyl
P00494659A0391|51 79|hydroxymethyl-2-oxazolidinone
P00494659A0391|85 95|glucuronide
P00495097A0663|5 19|characteristics
P00497494A0112|3 13|ventilation
P00497494A0112|32 36|PACO2
P00503336A0285|16 19|CAEC
P00503336A0285|29 30|CC
P00503336A0285|34 37|CIEC
P00503336A0285|103 115|transaminases
P00509703A0581|5 15|differences
P00510341T0036|11 20|E.O.R.T.C.
P00512215A0000|59 63|f2-f1
P00512215A0000|110 111|f1
P00512215A0000|113 117|f2/f1
P00512215A0000|118 119|f2
P00512215A0000|132 133|f1
P00512215A0000|136 137|L1
P00512215A0000|139 140|L2
P00512215A0000|145 146|L1
P00512215A0000|148 149|L2
P00513284A0000|26 36|doxycycline
P00513284A0000|37 40|DOTC
P00513284A0000|191 194|DOTC
P00516545T0001|10 24|characteristics
P00516545T0001|114 131|glomerulonephritis
P00517890A0468|35 46|transmission
P00519173A0126|39 50|oesophagitis
P00524451A0136|72 82|amphetamine
P00524451A0136|108 120|hexobarbitone
P00524451A0136|154 167|catecholamines
P00528144T0000|11 21|transferrin
P00534613A0000|0 10|Irradiation
P00534613A0000|36 39|UV-A
P00540707A0255|58 70|complications
P00541752A1032|7 20|determinations
P00541752A1032|128 129|SD
P00553858A0000|111 122|publications
P00555495T0000|7 22|re-establishment
P00555495T0000|39 49|termination
P00555495T0000|88 100|re-appearance
P00555583T0000|0 15|Pharmacokinetics
P00555583T0000|18 30|Carbamazepine
P00557559A0170|52 77|N-methylnitrone 1,4-dioxide
P00564943A0444|9 16|MCT-milk
P00564943A0444|71 78|SBO-milk
P00565136T0000|55 58|CH2O
P00565136T0000|60 65|SO2Cl2
P00565136T0000|70 72|Br2
P00569989A0239|48 51|PnCG
P00569989A0239|74 101|acceleration pneumocardiogram
P00569989A0239|105 110|dPn/dt
P00574222T0000|16 27|implications
P00574222T0000|31 41|development
P00574956A0304|115 125|equilibrium
P00574956A0304|226 236|development
P00574956A0304|253 265|manifestation
P00575231A0422|9 23|cystometrograms
P00577440A0298|60 81|3H-alpha-acetyldigoxin
P00578648T0048|34 47|administration
P00580151A0706|117 127|convenience
P00583004A0445|10 33|1,8-dihydroxy-9-anthrone
P00583004A0445|35 60|1,8,9-triacetoxyanthracene
P00583004A0445|64 87|1,8-diacetoxy-9-anthrone
P00583522T0001|52 63|inflammation
P00589073A0000|173 183|infertility
P00590594T0000|7 25|allotransplantation
P00592887T0000|40 51|lymphography
P00593119T0001|27 39|determination
P00593119T0001|42 44|IgE
P00593119T0001|50 62|comprehension
P00594466T0001|45 56|allylglycine
P00594466T0001|66 76|combination
P00594466T0001|99 109|stimulation
P00594617A0192|88 90|FDP
P00594617A0192|110 120|nephropathy
P00594617A0192|129 141|insufficiency
P00597715A0256|0 8|One-third
P00597715A0256|21 31|azoospermia
P00599601A0260|64 75|pinealectomy
P00600943T0001|13 31|lymphomononucleosis
P00603783A0647|13 15|IgG
P00603783A0647|19 21|IgM
P00606849T0000|41 53|thromboxane A2
P00614915T0001|18 29|traumatology
P00616575A0000|10 20|sensitivity
P00616575A0000|100 102|EMF
P00616575A0000|106 107|DW
P00616575A0000|117 129|investigation
P00617815A0215|12 25|L-R differences
P00618078A0367|54 64|improvement
P00619782A0058|93 96|UV-A
P00619948A0000|74 85|fluphenazine
P00619948A0000|94 106|nortriptyline
P00619948A0000|144 146|CNV
P00619948A0000|314 324|propranolol
P00621626T0000|15 36|affiliation preferences
P00623361A0221|28 39|contribution
P00623361A0221|51 61|dysfunction
P00627039T0000|0 10|Elimination
P00627202T0000|23 34|pharmacology
P00628990A0000|86 104|ureteroureterostomy
P00628990A0000|170 181|ureterostomy
P00635143T0001|8 19|strontium-90
P00637637T0000|57 68|hypertension
P00641395A0441|30 47|hyperbilirubinemia
P00641395A0441|67 77|measurement
P00641395A0441|80 82|ZPP
P00641395A0441|89 99|fluorimeter
P00644314T0000|7 22|hypersensitivity
P00644314T0000|46 60|anticoagulation
P00644539A0783|53 56|FEV1
P00657551T0000|0 10|Measurement
P00657551T0000|48 51|26Mg
P00663166A0000|172 174|PDA
P00665053A0276|38 42|06a6b
P00665053A0276|45 47|K13
P00665053A0276|49 50|H1
P00681550A0000|91 102|relationship
P00681550A0000|152 162|termination
P00685922A0451|70 72|IHB
P00693987T0001|0 13|Thromboplastic
P00693987T0001|52 65|administration
P00696680A0000|71 87|rhabdomyosarcomas
P00696680A0000|107 117|endometrium
P00702773A0327|84 86|RBF
P00702773A0327|88 90|GFR
P00703350A0418|29 33|99mTc
P00703932A0000|15 32|glomerulonephritis
P00703932A0000|35 45|association
P00704675A0199|9 11|UO2
P00704675A0199|46 56|bifurcation
P00712117A0521|71 79|A/Texas/1
P00712117A0521|107 118|A/Victoria/3
P00713525A0268|69 80|presentation
P00715180T0074|21 31|alterations
P00715753A0241|40 42|CPK
P00715753A0241|115 119|CK-MB
P00716366T0001|7 19|determination
P00722298A0619|63 73|differences
P00722298A0619|123 134|significance
P00725257A0452|40 42|DHE
P00725534A0888|66 79|IgA immunocytes
P00725752T0001|11 22|hypertension
P00725752T0001|28 38|combination
P00725752T0001|90 100|vasodilator
P00729003A1182|19 29|transcripts
P00733067A0188|149 159|anastomosis
P00733067A0188|233 243|anastomosis
P00740409A0000|3 16|histochemistry
P00740409A0000|20 33|ultrastructure
P00745775A0170|45 57|arteriography
P00748978T0000|20 34|prostaglandin E2
P00753237A0000|90 93|PAIN
P00753237A0000|161 163|PPU
P00753237A0000|177 187|combination
P00753237A0000|190 202|INSENSITIVITY
P00753237A0000|206 214|TRAUMATIS
P00753237A0000|371 381|compression
P00753237A0000|468 478|prophylaxis
P00753237A0000|481 483|PPU
P00755671A0485|66 76|development
P00755869A0216|0 21|Contingency contracting
P00755869A0216|44 61|parents/caregivers
P00755869A0216|78 89|consequences
P00755869A0216|98 112|self-monitoring
P00759049A0185|3 13|micromethod
P00759049A0185|18 30|microcuvettes
P00759049A0185|93 96|ICSH
P00759400T0000|17 20|5-HT
P00759400T0000|26 29|5-HT
P00762763A0253|21 24|SIDS
P00764737X0000|22 32|measurement
P00767161A0837|87 100|administration
P00779272T0001|61 73|mononucleosis
P00780639X0000|23 25|CEA
P00792847A0000|43 45|ALG
P00807356T0001|40 59|hydroxy-9 ellipticine
P00808898A0000|78 81|IPRF
P00811852T0001|8 19|satisfaction
P00818380A0239|128 138|populations
P00822611A0467|77 89|binephrectomy
P00825571T0031|0 2|III
P00827364A0000|32 48|freeze-fracturing
P00830568A0000|69 71|LTM
P00830568A0000|126 136|gastrectomy
P00830568A0000|141 158|gastroduodenostomy
P00830568A0000|159 164|STG-BI
P00830568A0000|173 189|gastrojejunostomy
P00830568A0000|190 196|STG-BII
P00830568A0000|235 246|pyloroplasty
P00830568A0000|247 249|V&P
P00833472A0907|54 64|institution
P00833472A0907|109 119|cholesterol
P00836637A0000|65 79|music-listening
P00836637A0000|172 184|reinforcement
P00837262A0000|3 16|responsiveness
P00837262A0000|31 32|VC
P00837262A0000|56 57|SC
P00837262A0000|94 105|conditioning
P00837262A0000|106 107|ON
P00837262A0000|112 114|OFF
P00837262A0000|117 127|stimulation
P00837811A0675|12 13|MS
P00837811A0675|88 100|abnormalities
P00838152A0863|109 121|disappearance
P00838152A0863|134 147|qualifications
P00838152A0863|175 186|predominance
P00838152A0863|203 216|qualifications
P00846559A0000|55 62|U.S.S.R.
P00846559A0000|132 137|U.S.A.
P00868301A0043|41 72|2-benzylidenamio-1-phenylpropane
P00870859A0121|71 83|recirculation
P00872442T0000|12 20|L-alanine
P00874942T0000|25 35|prematurity
P00877857A0763|72 80|mEq/liter
P00879329A0176|101 104|mmHg
P00879329A0176|147 149|IIp
P00879829A0564|35 37|IVH
P00881630A0000|90 104|Phospholipase-A
P00885562A0281|5 8|GAGs
P00885562A0281|78 91|osteoarthrosis
P00891370A0000|52 66|xeroradiography
P00891370A0000|94 108|contrast-medium
P00892353A0686|2 12|hypotension
P00898500A0246|56 57|HD
P00898500A0246|113 116|RAST
P00903772A0359|20 42|conditioning stimulation
P00909114A0000|0 17|Diallylnitrosamine
P00909114A0000|18 20|DAN
P00909114A0000|35 46|nitrosamines
P00910823A0196|64 65|pH
P00913623A0242|113 123|capillaries
P00915090A0536|34 36|mCi
P00915090A0536|39 44|Tc-99m
P00916099A0000|0 16|Self-emasculation
P00917572T0001|0 10|Possibility
P00917572T0001|47 60|hypothyroidism
P00918556A0000|39 43|HBsAg
P00918556A0000|49 56|anti-HBs
P00918965A0728|72 82|ventilation
P00918965A0728|90 101|componenents
P00918965A0728|171 174|PAO2
P00921911A0159|12 14|PGF
P00921911A0159|18 21|PGFM
P00926272A0000|25 37|deterioration
P00926604A0504|0 10|Propranolol
P00926604A0504|98 108|development
P00930947A0629|78 80|PZA
P00932738A0116|24 25|BP
P00932738A0116|32 35|mmHg
P00932738A0116|37 53|C02 responsiveness
P00932738A0116|99 100|BP
P00932817A0499|0 9|Iodine-123
P00932817A0499|44 46|MEC
P00932817A0499|124 128|99mTc
P00935526A0000|3 14|difficulties
P00935526A0000|24 37|prostaglandins
P00935526A0000|38 39|PG
P00935526A0000|91 101|sensitivity
P00938594A0149|61 74|manifestations
P00938594A0149|105 107|HOA
P00938594A0149|168 169|RA
P00947327A0000|121 136|sulfamethoxazole
P00947327A0000|137 139|SMZ
P00947327A0000|142 153|trimethoprim
P00947327A0000|154 156|TMP
P00947327A0000|159 169|combination
P00947327A0000|189 199|antibiotics
P00947327A0000|253 263|combination
P00947327A0000|266 267|N1
P00947327A0000|294 306|sulfanilamide
P00947327A0000|309 319|sulfamoxole
P00947327A0000|325 337|2,4-diamino-5
P00947327A0000|339 361|3,4,5-trimethoxy-benzyl
P00947327A0000|375 386|trimethoprim
P00947327A0000|402 403|CN
P00947327A0000|455 461|TMP/SMZ
P00947834X0000|0 6|RESULTS
P00951909X0001|135 156|Billroth-II gastrectomy
P00952734T0000|89 92|PECL
P00954819A1041|72 83|intoxication
P00962222A0633|67 92|erythrocyte characteristics
P00962277T0000|0 12|Haemodilution
P00970320A0000|3 13|performance
P00970320A0000|64 66|SO2
P00970488A0105|152 163|neuroleptics
P00970488A0105|170 180|development
P00974901A0080|0 10|Stimulation
P00974901A0080|105 118|susceptibility
P00975314T0001|7 17|amenorrhoea
P00975314T0001|82 95|gonadoblastoma
P00975540T0000|41 51|application
P00980255T0000|0 10|Application
P00985110T0001|8 18|projections
P00986925A0002|55 66|pentagastrin
P00986925A0002|133 136|47Ca
P00988572A0000|35 38|PLO2
P00993176A0066|133 135|NH4
P00996272A0397|39 49|variability
P00996272A0397|62 74|investigation
P00996272A0397|101 112|instructions
P01004298A0744|4 13|up-grading
P01009451A0728|23 24|UB
P01009451A0728|89 100|nocturnality
P01009739T0001|8 19|indomethacin
P01009739T0001|30 40|circulation
P01009739T0001|50 52|ECG
P01009841T0001|4 14|innervation
P01012640T0001|7 21|characteristics
P01012640T0001|48 63|pheochromocytoma
P01012904A0333|59 69|populations
P01019207A0232|87 89|lgC
P01021091T0000|109 119|Octapressin
P01044338A0240|8 19|measurements
P01048968A0152|44 56|staphylococci
P01048968A0152|84 95|erythromycin
P01048968A0152|108 121|beta-lactamase
P01050144A0297|66 76|antibiotics
P01050400T0000|0 10|Improvement
P01057137A0192|25 37|acceptability
P01078982A0227|52 67|cyclophosphamide
P01078982A0227|91 93|ALG
P01078982A0227|109 125|ALG administration
P01078982A0227|150 165|cyclophosphamide
P01081904A0198|59 79|pull-out arteriography
P01082726A0248|44 49|DC-ERG
P01082833A0000|83 94|indomethacin
P01082833A0000|95 96|IM
P01083375T0000|0 17|Alpha-1 antitrypsin
P01084413A0271|43 45|EMI
P01087288T0000|80 89|iodine-131
P01090210A0417|232 242|differences
P01092248T0000|34 45|pathogenesis
P01093845A0208|27 37|Delta-9-THC
P01093845A0208|48 58|voluntaries
P01093845A0208|107 119|modifications
P01093847A0000|21 44|tropatepine hydrochloride
P01093847A0000|82 93|neuroleptics
